Roche has signed a deal with Belgian biotech reMYND to develop new treatments for patients with Alzheimer’s and Parkinson’s disease. …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

